- Home
- RMI vs ANVS Comparison
RMI vs ANVS Comparison
Compare RMI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMI | ANVS |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 111.3M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RMI | ANVS |
|---|---|---|
| Price | $16.00 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 57.8K | ★ 313.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $1.11 |
| 52 Week High | $16.36 | $5.50 |
Technical Indicators
Market Signals| Indicator | RMI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 41.56 |
| Support Level | $14.15 | $2.27 |
| Resistance Level | $16.36 | $2.63 |
| Average True Range (ATR) | 0.40 | 0.20 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 76.00 | 12.31 |
Price Performance
Historical ComparisonAbout RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.